Диссертация (1335905), страница 29
Текст из файла (страница 29)
Dusilová-Sulková, R. Šafránek, J.Vávrová, J. Horáček, L. Pavlíková, V. Palička // Int Urol Nephrol. – 2015. –Vol.47, №1. – P. 169-76.160. Sullivan, C. Effect of food additives on hyperphosphatemia among patientswith end-stage renal disease: a randomized controlled trial / C.
Sullivan, S.S.Sayre, J.B. Leon, R. Machekano, T.E. Love, D. Porter, M. Marbury, A.R.Sehgal // JAMA. - 2009. – Vol.301, №6. – P. 629-35.164161. Tanaka, R. Long-term prognosis of parathyroid function in chronic dialysispatients after PEIT—a single-centre trial / R. Tanaka, T. Kakuta, F. Koiwa, M.Fukagawa and A. Saito // NDT Plus. - 2008. – Vol.1(Suppl 3). – P. 29-34.162. Tatsumi, R. Cinacalcet induces apoptosis in parathyroid cells in patientswith secondary hyperparathyroidism: histological and cytological analyses / R.Tatsumi, H. Komaba, G. Kanai, T. Miyakogawa, K.
Sawada, T. Kakuta, M.Fukagawa // Nephron Clin Pract. – 2013. – Vol.124, №3-4. – P. 224-31.163. Teng, M. Activated injectable vitamin D and hemodialysis survival: ahistorical cohort study / M. Teng, M. Wolf, M.N. Ofsthun, J.M. Lazarus, M.A.Hernán, C.A. Jr. Camargo, R. Thadhani // J Am Soc Nephrol. – 2005. – Vol.16,№4. – P.
1115-25.164. Teng, M. Survival of patients undergoing hemodialysis with paricalcitol orcalcitriol therapy / M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J.M. Lazarus, R.Thadhani // N Engl J Med. – 2003. – Vol. 349, №5. – P. 446-56.165. Tentori, F. High rates of death and hospitalization following bone fractureamong hemodialysis patients/ F. Tentori, K.P McCullough, R.D. Kilpatrick,B.D.
Bradbury, B.M. Robinson, P.G. Kerr, R.L. Pisoni // Kidney Int. - 2014. –Vol. 85, №1. – P. 166-173.166. Tentori, F. Mortality risk for dialysis patients with different levels of serumcalcium, phosphorus, and PTH: the Dialysis Outcomes and Practice PatternsStudy (DOPPS) / F. Tentori, M.J. Blayney, J.M. Albert, B.W. Gillespie, P.G.Kerr, J. Bommer, E.W.
Young, T. Akizawa, T. Akiba, R.L. Pisoni, B.M.Robinson, F.K. Port // Am J Kidney Dis. – 2008. – Vol.52, №3. – P. 519–530.167. Tentori, F. Recent changes in therapeutic approaches and association withoutcomes among patients with secondary hyperparathyroidism on chronichemodialysis: the DOPPS study/ F.
Tentori, M. Wang, B.A. Bieber, A.Karaboyas, Y. Li, S.H. Jacobson, V.E. Andreucci, M. Fukagawa, L. Frimat,D.C. Mendelssohn, F.K. Port, R.L. Pisoni, B.M. Robinson // Clin J Am SocNephrol. – 2015. – Vol.10, №1. – P. 98-109.165168. Tomilina, N. The dialysis outcomes and practice patterns study (DOPPS) inRussia: Study design and initial comparisons with the Russian RRT registry.[MP563]/ N.
Tomilina, B. Bikbov, A. Andrusev, A. Zemchenkov, B. Bieber,B.M. Robinson, R.L. Pisoni // Nephrol Dial Transpl. – 2014. – Vol.29 (Suppl3). – P. 519.169. Tominaga, Y. Clinical features and hyperplastic patterns of parathyroidglands in hemodialysis patients with advanced secondary hyperparathyroidismrefractory to maxacalcitol treatment and required parathyroidectomy / Y.Tominaga, S. Matsuoka, T.
Sato, N. Uno, N. Goto, A. Katayama, T. Haba //Ther Apher Dial. – 2007. – Vol.11, №4. – P. 266-73.170. Tominaga, Y. Histopathology, pathophysiology, and indications for surgicaltreatment of renal hyperparathyroidism / Y. Tominaga, Y. Tanaka, K. Sato, T.Nagasaka, H. Takagi // Seminars in Surgical Oncology. – 1997. – Vol.13. – P.78-86.171. Tominaga, Y. Re-operation is frequently required when parathyroid glandsremain after initial parathyroidectomy for advanced secondary HPT in uremicpatients / Y.
Tominaga, A. Katayama, T. Sato, S. Matsuoka, N. Goto, T. Haba,Y. Hibi, M. Numano, T. Ichimori, K. Uchida // Nephrol Dial. Transplant. –2003. – Vol.18, №3. – P. 65-70.172. Tonelli, M. Phosphate removal with several thrice-weekly dialysis methodsin overweight hemodialysis patients / M. Tonelli, W. Wang, B.
Hemmelgarn,A. Lloyd, B. Manns // Am. J. Kidney. Dis. – 2009. – Vol.54, №6. – P. 1108–1115.173. Torregrosa,J.V.Setpointofcalciuminseveresecondaryhyperparathyroidism is altered and does not change after successful kidneytransplantation / J.V. Torregrosa, D. Fuster, C.E. Duran, F. Oppenheimer, Á.Muxí, D.
Rubello, F. Pons, J.M. Campistol // Endocrine. - 2015. – Vol.48, №2.– P. 709-11.174. Uhlig, K. KDOQI US commentary on the 2009 KDIGO Clinical PracticeGuideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and166Bone Disorder (CKD-MBD) / K. Uhlig, J.S. Berns, B. Kestenbaum, R. Kumar,M.B. Leonard, K.J. Martin, S.M. Sprague, S. Goldfarb // Am J Kidney Dis.
–2010. – Vol.55, №5. – P. 773-99.175. Uribarri, J. Phosphorus additives in food and their effect in dialysis patients /J. Uribarri // Clin J Am Soc Nephrol. – 2009. – Vol.4, №8. – P. 1290-2.176. Vulpio, C. Parathyroid-gland ultrasonography in clinical and therapeuticevaluation of renal secondary hyperparathyroidism / C. Vulpio, M. Bossola,S.C. Magalini, P. Silvestri, G.
Fadda, M. Ciliberti, M.L. D'Andrea, G. Maresca// Radiol Med. – 2013. – Vol.118, №5. – P. 707-22.177. Wada, M. The calcimimetic compound NPS R-568 suppresses parathyroidcell proliferation in rats with renal insufficiency. Control of parathyroid cellgrowth via a calcium receptor / M. Wada, Y. Furuya, J. Sakiyama, N.Kobayashi, S. Miyata, H. Ishii, N.
Nagano // J Clin Invest. – 1997. – Vol.100,№12. – P. 2977-2983.178. Ward, R.A. Resistance to intercompartmental mass transfer limits beta2microglobulin removal by post-dilution hemodiafiltration / R.A. Ward, T.Greene, B. Hartmann, W.
Samtleben // Kidney Int. – 2006. – Vol.69, №8. – P.1431–1437.179. Wetmore, J.B. A Randomized Trial of Cinacalcet versus Vitamin D Analogsas Monotherapy in Secondary Hyperparathyroidism (PARADIGM)/ J.B.Wetmore, K. Gurevich, S. Sprague, G. Da Roza, J. Buerkert, M. Reiner, W.Goodman, K. Cooper // Clin J Am Soc Nephrol. – 2015. – Vol.
10, №6. – P.1031-40.180. Wolisi, G.O. The role of vitamin D in vascular calcification in chronickidney disease / G.O. Wolisi, S.M. Moe // Semin Dial – 2005. – V.18. – P.307-314.181. Wu, M.H. Electron beam computed tomography evidence of aorticcalcification as an independent determinant of coronary artery calcification /M.H.
Wu, M.S. Chern, L.C. Chen, Y.P. Lin, M.H. Sheu, J.C. Liu, C.Y. Chang //J Chin Med Assoc. – 2006. – Vol.69, №9. – P. 409-14.167182. Wüthrich, R.P. Randomized clinical trial of the iron-based phosphate binderPA21 in hemodialysis patients / R.P. Wüthrich, M. Chonchol, A. Covic, S.Gaillard, E. Chong, J.A. Tumlin // Clin J Am Soc Nephrol. - 2013. – Vol.8, №2– P. 280–289.183. Wu-Wong, J.R. Effects of vitamin D analogs on gene expression profiling inhuman coronary artery smooth muscle cells / J.R. Wu-Wong, M. Nakane, J.Ma, X.
Ruan, P.E. Kroeger // Atherosclerosis. – 2006. – V.186. – P. 20-28.184. Xu, R. Comparison of the prevalence of chronic kidney disease amongdifferent ethnicities: Beijing CKD survey and American NHANES / R.Xu, L.Zhang, P. Zhang, F. Wang, L. Zuo, H Wang //Nephrol Dial Transplant. - 2009.– Vol.24, №4. – P. 1220-6.185. Yamada, S. Two Years of Cinacalcet Hydrochloride Treatment DecreasedParathyroid Gland Volume and Serum Parathyroid Hormone Level inHemodialysis Patients With Advanced Secondary Hyperparathyroidism / S.Yamada, M. Tokumoto, M. Taniguchi, J.
Toyonaga, T. Suehiro, R. Eriguchi, S.Fujimi, H. Ooboshi, T. Kitazono, K. Tsuruya // Ther Apher Dial. – 2015. –Vol.19, №4. – P. 367-77.186. Yamamoto, M. Number of enlarged parathyroid glands might be a predictorof cinacalcet response in advanced secondary hyperparathyroidism / M.Yamamoto, H.
Ogata, M. Mizobuchi, N. Yoshida, C. Kumata-Maeta, F. Koiwa,K. Shishido, E. Kinugasa // Clin Exp Nephrol. – 2012. – Vol.16, №2. – P. 2929.187. Zhang, L. Total parathyroidectomy in treatment of Sagliker syndrome in 10cases of hemodialysing patients with secondary hyperparathyroidism / L.Zhang, L. Yao, Z. Hua, W.J. Bian, W.G. Li // Zhonghua Nei Ke Za Zhi. – 2011.– Vol.50, №7. – P. 562-7.188. Zheng, Z. Vitamin D supplementation and mortality risk in chronic kidneydisease: a meta-analysis of 20 observational studies / Z.
Zheng, H. Shi, J. Jia, D.Li, S. Lin // BMC Nephrol. – 2013. – Vol.14. – P. 199..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
